Andy Weymann

Andy is highly experienced at identifying relevant target technologies and companies in regenerative medicine. He has assessed many of them over the years and has been instrumental in the assessment of new treatment options and lead many key integrations. In addition, Andy has been very successful at supporting global launches and scaling the commercial successes of these technologies in key geographies. He worked closely with research and development teams as well as his clinical team, identifying key evidence needs and building global communities as investigators as well as clinical thought leaders either in their countries, regionally or globally.

Andy joined Jellagen’s team in 2020. He brings 25 years of experience in global and executive roles in medical device and regenerative medicine organizations.

Immediately prior to joining Jellagen, Andy was Chief Medical Officer (CMO) for Smith+Nephew, where he provided global executive leadership and oversight of Clinical, Scientific and Medical Affairs with accountability for business development, patient and product safetly. He was also a Board Member of S+N Switzerland and a Board Member of Actracsys, a company acquired by S+N. Prior to his corporate career, Andy was a physician in Switzerland practising in trauma, orthopaedic surgery and sports medicine, having obtained his Masters in Human Medicine at the University of Zurich, Switzerland. Following his time as a Medical Doctor, Andy completed his MBA degree at the Simon Business School, University of Rochester NY as well expanding his experience with the board program at the Harvard Business School in Boston MA.